Search

Your search keyword '"Tonn, Joerg-Christian"' showing total 893 results
Start Over Author "Tonn, Joerg-Christian"
893 results on '"Tonn, Joerg-Christian"'

1. Joint EANM/EANO/RANO/SNMMI practice guideline/procedure standards for diagnostics and therapy (theranostics) of meningiomas using radiolabeled somatostatin receptor ligands: version 1.0

Author

Albert, Nathalie L., Preusser, Matthias, Traub-Weidinger, Tatjana, Tolboom, Nelleke, Law, Ian, Palmer, Joshua D., Guedj, Eric, Furtner, Julia, Fraioli, Francesco, Huang, Raymond Y., Johnson, Derek R., Deroose, Christophe M., Herrmann, Ken, Vogelbaum, Michael, Chang, Susan, Tonn, Joerg-Christian, Weller, Michael, Wen, Patrick Y., van den Bent, Martin J., Verger, Antoine, Ivanidze, Jana, and Galldiks, Norbert

Published
2024
Full Text
View/download PDF

6. Surgical management and outcome of newly diagnosed glioblastoma without contrast enhancement (low-grade appearance): a report of the RANO resect group.

Author

Karschnia, Philipp, Dietrich, Jorg, Bruno, Francesco, Dono, Antonio, Juenger, Stephanie, Teske, Nico, Young, Jacob, Sciortino, Tommaso, Häni, Levin, van den Bent, Martin, Weller, Michael, Vogelbaum, Michael, Morshed, Ramin, Haddad, Alexander, Molinaro, Annette, Tandon, Nitin, Beck, Juergen, Schnell, Oliver, Bello, Lorenzo, Hervey-Jumper, Shawn, Thon, Niklas, Grau, Stefan, Esquenazi, Yoshua, Rudà, Roberta, Chang, Susan, Berger, Mitchel, Cahill, Daniel, and Tonn, Joerg-Christian

Subjects
WHO 2021, contrast enhancement, extent of resection, glioblastoma, surgery, Humans, Glioblastoma, Retrospective Studies, Brain Neoplasms, Prognosis, Magnetic Resonance Imaging
Abstract

BACKGROUND: Resection of the contrast-enhancing (CE) tumor represents the standard of care in newly diagnosed glioblastoma. However, some tumors ultimately diagnosed as glioblastoma lack contrast enhancement and have a low-grade appearance on imaging (non-CE glioblastoma). We aimed to (a) volumetrically define the value of non-CE tumor resection in the absence of contrast enhancement, and to (b) delineate outcome differences between glioblastoma patients with and without contrast enhancement. METHODS: The RANO resect group retrospectively compiled a global, eight-center cohort of patients with newly diagnosed glioblastoma per WHO 2021 classification. The associations between postoperative tumor volumes and outcome were analyzed. Propensity score-matched analyses were constructed to compare glioblastomas with and without contrast enhancement. RESULTS: Among 1323 newly diagnosed IDH-wildtype glioblastomas, we identified 98 patients (7.4%) without contrast enhancement. In such patients, smaller postoperative tumor volumes were associated with more favorable outcome. There was an exponential increase in risk for death with larger residual non-CE tumor. Accordingly, extensive resection was associated with improved survival compared to lesion biopsy. These findings were retained on a multivariable analysis adjusting for demographic and clinical markers. Compared to CE glioblastoma, patients with non-CE glioblastoma had a more favorable clinical profile and superior outcome as confirmed in propensity score analyses by matching the patients with non-CE glioblastoma to patients with CE glioblastoma using a large set of clinical variables. CONCLUSIONS: The absence of contrast enhancement characterizes a less aggressive clinical phenotype of IDH-wildtype glioblastomas. Maximal resection of non-CE tumors has prognostic implications and translates into favorable outcome.

Published
2024

7. A framework for standardised tissue sampling and processing during resection of diffuse intracranial glioma: joint recommendations from four RANO groups

Author

Karschnia, Philipp, Smits, Marion, Reifenberger, Guido, Le Rhun, Emilie, Ellingson, Benjamin M, Galldiks, Norbert, Kim, Michelle M, Huse, Jason T, Schnell, Oliver, Harter, Patrick N, Mohme, Malte, Panel, Rater, Aldape, Kenneth, Baehring, Joachim M, Bello, Lorenzo, Brat, Daniel J, Cahill, Daniel P, Chung, Caroline, Colman, Howard, Dietrich, Jorg, Drummond, Katharine, Esquenazi, Yoshua, Gerstner, Elizabeth R, Furtner, Julia, Garibotto, Valentina, Kaufmann, Timothy J, Komori, Takashi, Kotecha, Rupesh, Liau, Linda M, Lupo, Janine M, Minniti, Giuseppe, Narita, Yoshitaka, Niyazi, Maximilian, Perry, Arie, Preusser, Matthias, Rudà, Roberta, Sanai, Nader, Schmidt, Nils-Ole, Steinbach, Joachim P, Thust, Stefanie C, Tolboom, Nelleke, van der Hoorn, Anouk, van der Vaart, Thijs, Verger, Antoine, Vik-Mo, Einar Osland, Watts, Colin, Westphal, Manfred, Wesseling, Pieter, Young, Jacob S, von Baumgarten, Louisa, Albert, Nathalie L, Huang, Raymond Y, Mehta, Minesh P, van den Bent, Martin, Weller, Michael, Vogelbaum, Michael A, Chang, Susan M, Berger, Mitchel S, and Tonn, Joerg-Christian

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Brain Cancer, Brain Disorders, Rare Diseases, Neurosciences, Cancer, Humans, Brain Neoplasms, Prospective Studies, Biological Specimen Banks, Neoplasm Recurrence, Local, Glioma, Expert Rater Panel, Oncology & Carcinogenesis, Oncology and carcinogenesis
Abstract

Surgical resection represents the standard of care for people with newly diagnosed diffuse gliomas, and the neuropathological and molecular profile of the resected tissue guides clinical management and forms the basis for research. The Response Assessment in Neuro-Oncology (RANO) consortium is an international, multidisciplinary effort that aims to standardise research practice in neuro-oncology. These recommendations represent a multidisciplinary consensus from the four RANO groups: RANO resect, RANO recurrent glioblastoma, RANO radiotherapy, and RANO/PET for a standardised workflow to achieve a representative tumour evaluation in a disease characterised by intratumoural heterogeneity, including recommendations on which tumour regions should be surgically sampled, how to define those regions on the basis of preoperative imaging, and the optimal sample volume. Practical recommendations for tissue sampling are given for people with low-grade and high-grade gliomas, as well as for people with newly diagnosed and recurrent disease. Sampling of liquid biopsies is also addressed. A standardised workflow for subsequent handling of the resected tissue is proposed to avoid information loss due to decreasing tissue quality or insufficient clinical information. The recommendations offer a framework for prospective biobanking studies.

Published
2023

8. Prognostic evaluation of re-resection for recurrent glioblastoma using the novel RANO classification for extent of resection: A report of the RANO resect group.

Author

Karschnia, Philipp, Dono, Antonio, Young, Jacob, Juenger, Stephanie, Teske, Nico, Häni, Levin, Sciortino, Tommaso, Mau, Christine, Bruno, Francesco, Nunez, Luis, Morshed, Ramin, Haddad, Alexander, Weller, Michael, van den Bent, Martin, Beck, Juergen, Hervey-Jumper, Shawn, Tandon, Nitin, Rudà, Roberta, Vogelbaum, Michael, Bello, Lorenzo, Schnell, Oliver, Grau, Stefan, Chang, Susan, Berger, Mitchel, Esquenazi, Yoshua, Tonn, Joerg-Christian, and Molinaro, Annette

Subjects
classification, extent of resection, glioblastoma recurrence, outcome, surgical re-resection, Humans, Glioblastoma, Prognosis, Retrospective Studies, Brain Neoplasms
Abstract

BACKGROUND: The value of re-resection in recurrent glioblastoma remains controversial as a randomized trial that specifies intentional incomplete resection cannot be justified ethically. Here, we aimed to (1) explore the prognostic role of extent of re-resection using the previously proposed Response Assessment in Neuro-Oncology (RANO) classification (based upon residual contrast-enhancing (CE) and non-CE tumor), and to (2) define factors consolidating the surgical effects on outcome. METHODS: The RANO resect group retrospectively compiled an 8-center cohort of patients with first recurrence from previously resected glioblastomas. The associations of re-resection and other clinical factors with outcome were analyzed. Propensity score-matched analyses were constructed to minimize confounding effects when comparing the different RANO classes. RESULTS: We studied 681 patients with first recurrence of Isocitrate Dehydrogenase (IDH) wild-type glioblastomas, including 310 patients who underwent re-resection. Re-resection was associated with prolonged survival even when stratifying for molecular and clinical confounders on multivariate analysis; ≤1 cm3 residual CE tumor was associated with longer survival than non-surgical management. Accordingly, maximal resection (class 2) had superior survival compared to submaximal resection (class 3). Administration of (radio-)chemotherapy in the absence of postoperative deficits augmented the survival associations of smaller residual CE tumors. Conversely, supramaximal resection of non-CE tumor (class 1) was not associated with prolonged survival but was frequently accompanied by postoperative deficits. The prognostic role of residual CE tumor was confirmed in propensity score analyses. CONCLUSIONS: The RANO resect classification serves to stratify patients with re-resection of glioblastoma. Complete resection according to RANO resect classes 1 and 2 is prognostic.

Published
2023

10. PD-1 blockade does not improve efficacy of EpCAM-directed CAR T-cell in lung cancer brain metastasis

Author

Blobner, Jens, Dengler, Laura, Eberle, Constantin, Herold, Julika J., Xu, Tao, Beck, Alexander, Mühlbauer, Anton, Müller, Katharina J., Teske, Nico, Karschnia, Philipp, van den Heuvel, Dominic, Schallerer, Ferdinand, Ishikawa-Ankerhold, Hellen, Thon, Niklas, Tonn, Joerg-Christian, Subklewe, Marion, Kobold, Sebastian, Harter, Patrick N., Buchholz, Veit R., and von Baumgarten, Louisa

Published
2024
Full Text
View/download PDF

13. Prognostic validation of a new classification system for extent of resection in glioblastoma: A report of the RANO resect group

Author

Karschnia, Philipp, Young, Jacob S, Dono, Antonio, Häni, Levin, Sciortino, Tommaso, Bruno, Francesco, Juenger, Stephanie T, Teske, Nico, Morshed, Ramin A, Haddad, Alexander F, Zhang, Yalan, Stoecklein, Sophia, Weller, Michael, Vogelbaum, Michael A, Beck, Juergen, Tandon, Nitin, Hervey-Jumper, Shawn, Molinaro, Annette M, Rudà, Roberta, Bello, Lorenzo, Schnell, Oliver, Esquenazi, Yoshua, Ruge, Maximilian I, Grau, Stefan J, Berger, Mitchel S, Chang, Susan M, van den Bent, Martin, and Tonn, Joerg-Christian

Subjects
Brain Disorders, Rare Diseases, Brain Cancer, Cancer, Neurosciences, Humans, Prognosis, Glioblastoma, Retrospective Studies, Brain Neoplasms, Neurosurgical Procedures, Treatment Outcome, EOR, classification, glioblastoma, outcome, surgical resection, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

BackgroundTerminology to describe extent of resection in glioblastoma is inconsistent across clinical trials. A surgical classification system was previously proposed based upon residual contrast-enhancing (CE) tumor. We aimed to (1) explore the prognostic utility of the classification system and (2) define how much removed non-CE tumor translates into a survival benefit.MethodsThe international RANO resect group retrospectively searched previously compiled databases from 7 neuro-oncological centers in the USA and Europe for patients with newly diagnosed glioblastoma per WHO 2021 classification. Clinical and volumetric information from pre- and postoperative MRI were collected.ResultsWe collected 1,008 patients with newly diagnosed IDHwt glioblastoma. 744 IDHwt glioblastomas were treated with radiochemotherapy per EORTC-26981/22981 (TMZ/RT→TMZ) following surgery. Among these homogenously treated patients, lower absolute residual tumor volumes (in cm3) were favorably associated with outcome: patients with "maximal CE resection" (class 2) had superior outcome compared to patients with "submaximal CE resection" (class 3) or "biopsy" (class 4). Extensive resection of non-CE tumor (≤5 cm3 residual non-CE tumor) was associated with better survival among patients with complete CE resection, thus defining class 1 ("supramaximal CE resection"). The prognostic value of the resection classes was retained on multivariate analysis when adjusting for molecular and clinical markers.ConclusionsThe proposed "RANO categories for extent of resection in glioblastoma" are highly prognostic and may serve for stratification within clinical trials. Removal of non-CE tumor beyond the CE tumor borders may translate into additional survival benefit, providing a rationale to explicitly denominate such "supramaximal CE resection."

Published
2023

14. Advances in PET imaging for meningioma patients.

Author

Galldiks, Norbert, Albert, Nathalie L, Wollring, Michael, Werner, Jan-Michael, Lohmann, Philipp, Villanueva-Meyer, Javier E, Fink, Gereon R, Langen, Karl-Josef, and Tonn, Joerg-Christian

Subjects
DOTATATE, FDG, FLT, SiTATE, amino acid PET, somatostatin receptor-expression, Brain Cancer, Brain Disorders, Biomedical Imaging, Cancer, Rare Diseases, Neurosciences, Detection, screening and diagnosis, 4.2 Evaluation of markers and technologies
Abstract

In patients with meningioma, diagnosis and treatment planning are predominantly based on anatomical imaging using MRI or CT. Constraints of these imaging modalities include precise meningioma delineation-especially at the skull base, in the case of trans-osseus growth, and in tumors with complex geometry-and the differentiation of post-therapeutic reactive changes from meningioma relapse. Advanced metabolic imaging using PET may help to characterize specific metabolic and cellular features providing additional information beyond the information derived from anatomical imaging alone. Accordingly, the use of PET in meningioma patients is steadily increasing. This review summarizes recent advances in PET imaging helpful for improving the clinical management of patients with meningioma.

Published
2023

16. A brave new framework for glioma drug development

Author

Hotchkiss, Kelly M, Karschnia, Philipp, Schreck, Karisa C, Geurts, Marjolein, Cloughesy, Timothy F, Huse, Jason, Duke, Elizabeth S, Lathia, Justin, Ashley, David M, Nduom, Edjah K, Long, Georgina, Singh, Kirit, Chalmers, Anthony, Ahluwalia, Manmeet S, Heimberger, Amy, Bagley, Stephen, Todo, Tomoki, Verhaak, Roel, Kelly, Patrick D, Hervey-Jumper, Shawn, de Groot, John, Patel, Anoop, Fecci, Peter, Parney, Ian, Wykes, Victoria, Watts, Colin, Burns, Terry C, Sanai, Nader, Preusser, Matthias, Tonn, Joerg Christian, Drummond, Katharine J, Platten, Michael, Das, Sunit, Tanner, Kirk, Vogelbaum, Michael A, Weller, Michael, Whittle, James R, Berger, Mitchel S, and Khasraw, Mustafa

Published
2024
Full Text
View/download PDF

17. The oncological role of resection in newly diagnosed diffuse adult-type glioma defined by the WHO 2021 classification: a Review by the RANO resect group

Author

Karschnia, Philipp, Gerritsen, Jasper K W, Teske, Nico, Cahill, Daniel P, Jakola, Asgeir S, van den Bent, Martin, Weller, Michael, Schnell, Oliver, Vik-Mo, Einar O, Thon, Niklas, Vincent, Arnaud J P E, Kim, Michelle M, Reifenberger, Guido, Chang, Susan M, Hervey-Jumper, Shawn L, Berger, Mitchel S, and Tonn, Joerg-Christian

Published
2024
Full Text
View/download PDF

19. A H3K27M-targeted vaccine in adults with diffuse midline glioma

Author

Grassl, Niklas, Poschke, Isabel, Lindner, Katharina, Bunse, Lukas, Mildenberger, Iris, Boschert, Tamara, Jähne, Kristine, Green, Edward W., Hülsmeyer, Ingrid, Jünger, Simone, Kessler, Tobias, Suwala, Abigail K., Eisele, Philipp, Breckwoldt, Michael O., Vajkoczy, Peter, Grauer, Oliver M., Herrlinger, Ulrich, Tonn, Joerg-Christian, Denk, Monika, Sahm, Felix, Bendszus, Martin, von Deimling, Andreas, Winkler, Frank, Wick, Wolfgang, Platten, Michael, and Sahm, Katharina

Published
2023
Full Text
View/download PDF

20. Long-term neurocognitive function and quality of life after multimodal therapy in adult glioma patients: a prospective long-term follow-up

Author

Pertz, Milena, Schlömer, Sabine, Seidel, Clemens, Hentschel, Bettina, Löffler, Markus, Schackert, Gabriele, Krex, Dietmar, Juratli, Tareq, Tonn, Joerg Christian, Schnell, Oliver, Vatter, Hartmut, Simon, Matthias, Westphal, Manfred, Martens, Tobias, Sabel, Michael, Bendszus, Martin, Dörner, Nils, Wick, Antje, Fliessbach, Klaus, Hoppe, Christian, Klingner, Marcel, Felsberg, Jörg, Reifenberger, Guido, Gramatzki, Dorothee, Weller, Michael, and Schlegel, Uwe

Published
2023
Full Text
View/download PDF

21. Next-generation PET/CT imaging in meningioma—first clinical experiences using the novel SSTR-targeting peptide [18F]SiTATE

Author

Unterrainer, Marcus, Kunte, Sophie C., Unterrainer, Lena M., Holzgreve, Adrien, Delker, Astrid, Lindner, Simon, Beyer, Leonie, Brendel, Matthias, Kunz, Wolfgang G., Winkelmann, Michael, Cyran, Clemens C., Ricke, Jens, Jurkschat, Klaus, Wängler, Carmen, Wängler, Björn, Schirrmacher, Ralf, Belka, Claus, Niyazi, Maximilian, Tonn, Joerg-Christian, Bartenstein, Peter, and Albert, Nathalie L.

Published
2023
Full Text
View/download PDF

23. Translocator protein (18kDA) (TSPO) marks mesenchymal glioblastoma cell populations characterized by elevated numbers of tumor-associated macrophages

Author

Weidner, Lorraine, Lorenz, Julia, Quach, Stefanie, Braun, Frank K., Rothhammer-Hampl, Tanja, Ammer, Laura-Marie, Vollmann-Zwerenz, Arabel, Bartos, Laura M., Dekorsy, Franziska J., Holzgreve, Adrien, Kirchleitner, Sabrina V., Thon, Niklas, Greve, Tobias, Ruf, Viktoria, Herms, Jochen, Bader, Stefanie, Milenkovic, Vladimir M., von Baumgarten, Louisa, Menevse, Ayse N., Hussein, Abir, Sax, Julian, Wetzel, Christian H., Rupprecht, Rainer, Proescholdt, Martin, Schmidt, Nils O., Beckhove, Philipp, Hau, Peter, Tonn, Joerg-Christian, Bartenstein, Peter, Brendel, Matthias, Albert, Nathalie L., and Riemenschneider, Markus J.

Published
2023
Full Text
View/download PDF

24. TSPO acts as an immune resistance gene involved in the T cell mediated immune control of glioblastoma

Author

Menevse, Ayse N., Ammer, Laura-Marie, Vollmann-Zwerenz, Arabel, Kupczyk, Marcell, Lorenz, Julia, Weidner, Lorraine, Hussein, Abir, Sax, Julian, Mühlbauer, Jasmin, Heuschneider, Nicole, Rohrmus, Celine, Mai, Laura S., Jachnik, Birgit, Stamova, Slava, Volpin, Valentina, Durst, Franziska C., Sorrentino, Antonio, Xydia, Maria, Milenkovic, Vladimir M., Bader, Stefanie, Braun, Frank K., Wetzel, Christian, Albert, Nathalie L., Tonn, Joerg-Christian, Bartenstein, Peter, Proescholdt, Martin, Schmidt, Nils O., Linker, Ralf A., Riemenschneider, Markus J., Beckhove, Philipp, and Hau, Peter

Published
2023
Full Text
View/download PDF

27. Deep-learning-based reconstruction of undersampled MRI to reduce scan times: a multicentre, retrospective, cohort study

Author

Rastogi, Aditya, Brugnara, Gianluca, Foltyn-Dumitru, Martha, Mahmutoglu, Mustafa Ahmed, Preetha, Chandrakanth J, Kobler, Erich, Pflüger, Irada, Schell, Marianne, Deike-Hofmann, Katerina, Kessler, Tobias, van den Bent, Martin J, Idbaih, Ahmed, Platten, Michael, Brandes, Alba A, Nabors, Burt, Stupp, Roger, Bernhardt, Denise, Debus, Jürgen, Abdollahi, Amir, Gorlia, Thierry, Tonn, Jörg-Christian, Weller, Michael, Maier-Hein, Klaus H, Radbruch, Alexander, Wick, Wolfgang, Bendszus, Martin, Meredig, Hagen, Kurz, Felix T, and Vollmuth, Philipp

Published
2024
Full Text
View/download PDF

29. PET-based response assessment criteria for diffuse gliomas (PET RANO 1.0): a report of the RANO group

Author

Albert, Nathalie L, Galldiks, Norbert, Ellingson, Benjamin M, van den Bent, Martin J, Chang, Susan M, Cicone, Francesco, de Groot, John, Koh, Eng-Siew, Law, Ian, Le Rhun, Emilie, Mair, Maximilian J, Minniti, Giuseppe, Rudà, Roberta, Scott, Andrew M, Short, Susan C, Smits, Marion, Suchorska, Bogdana, Tolboom, Nelleke, Traub-Weidinger, Tatjana, Tonn, Joerg-Christian, Verger, Antoine, Weller, Michael, Wen, Patrick Y, and Preusser, Matthias

Published
2024
Full Text
View/download PDF

31. A framework for standardised tissue sampling and processing during resection of diffuse intracranial glioma: joint recommendations from four RANO groups

Author

Aldape, Kenneth, Baehring, Joachim M., Bello, Lorenzo, Brat, Daniel J., Cahill, Daniel P., Chung, Caroline, Colman, Howard, Dietrich, Jorg, Drummond, Katharine, Esquenazi, Yoshua, Gerstner, Elizabeth R., Furtner, Julia, Garibotto, Valentina, Kaufmann, Timothy J., Komori, Takashi, Kotecha, Rupesh, Liau, Linda M., Lupo, Janine M., Minniti, Giuseppe, Narita, Yoshitaka, Niyazi, Maximilian, Perry, Arie, Preusser, Matthias, Rudà, Roberta, Sanai, Nader, Schmidt, Nils-Ole, Steinbach, Joachim P., Thust, Stefanie C., Tolboom, Nelleke, van der Hoorn, Anouk, van der Vaart, Thijs, Verger, Antoine, Vik-Mo, Einar Osland, Watts, Colin, Westphal, Manfred, Wesseling, Pieter, Young, Jacob S., Karschnia, Philipp, Smits, Marion, Reifenberger, Guido, Le Rhun, Emilie, Ellingson, Benjamin M, Galldiks, Norbert, Kim, Michelle M, Huse, Jason T, Schnell, Oliver, Harter, Patrick N, Mohme, Malte, von Baumgarten, Louisa, Albert, Nathalie L, Huang, Raymond Y, Mehta, Minesh P, van den Bent, Martin, Weller, Michael, Vogelbaum, Michael A, Chang, Susan M, Berger, Mitchel S, and Tonn, Joerg-Christian

Published
2023
Full Text
View/download PDF

34. TSPO PET signal using [18F]GE180 is associated with survival in recurrent gliomas

Author

Quach, Stefanie, Holzgreve, Adrien, Kaiser, Lena, Unterrainer, Marcus, Dekorsy, Franziska J., Nelwan, Debie V., Bartos, Laura M., Kirchleitner, Sabrina V., Weller, Jonathan, Weidner, Lorraine, Niyazi, Maximilian, Ruf, Viktoria C., Herms, Jochen, Stöcklein, Sophia, Wetzel, Christian, Riemenschneider, Markus J., v. Baumgarten, Louisa, Thon, Niklas, Brendel, Matthias, Rupprecht, Rainer, Bartenstein, Peter, Tonn, Joerg-Christian, and Albert, Nathalie L.

Published
2023
Full Text
View/download PDF

35. Combination of pre-treatment dynamic [18F]FET PET radiomics and conventional clinical parameters for the survival stratification in patients with IDH-wildtype glioblastoma

Author

Li, Zhicong, Holzgreve, Adrien, Unterrainer, Lena M., Ruf, Viktoria C., Quach, Stefanie, Bartos, Laura M., Suchorska, Bogdana, Niyazi, Maximilian, Wenter, Vera, Herms, Jochen, Bartenstein, Peter, Tonn, Joerg-Christian, Unterrainer, Marcus, Albert, Nathalie L., and Kaiser, Lena

Published
2023
Full Text
View/download PDF

36. Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions

Author

Wen, Patrick Y, Weller, Michael, Lee, Eudocia Quant, Alexander, Brian M, Barnholtz-Sloan, Jill S, Barthel, Floris P, Batchelor, Tracy T, Bindra, Ranjit S, Chang, Susan M, Chiocca, E Antonio, Cloughesy, Timothy F, DeGroot, John F, Galanis, Evanthia, Gilbert, Mark R, Hegi, Monika E, Horbinski, Craig, Huang, Raymond Y, Lassman, Andrew B, Le Rhun, Emilie, Lim, Michael, Mehta, Minesh P, Mellinghoff, Ingo K, Minniti, Giuseppe, Nathanson, David, Platten, Michael, Preusser, Matthias, Roth, Patrick, Sanson, Marc, Schiff, David, Short, Susan C, Taphoorn, Martin JB, Tonn, Joerg-Christian, Tsang, Jonathan, Verhaak, Roel GW, von Deimling, Andreas, Wick, Wolfgang, Zadeh, Gelareh, Reardon, David A, Aldape, Kenneth D, and van den Bent, Martin J

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Neurosciences, Rare Diseases, Cancer, Orphan Drug, Brain Cancer, Brain Disorders, 2.1 Biological and endogenous factors, Good Health and Well Being, Brain Neoplasms, Chemoradiotherapy, Clinical Trials, Phase III as Topic, Consensus, Glioblastoma, Humans, Isocitrate Dehydrogenase, Randomized Controlled Trials as Topic, glioblastoma, diagnosis, therapy, clinical trials, Oncology & Carcinogenesis, Oncology and carcinogenesis
Abstract

Glioblastomas are the most common form of malignant primary brain tumor and an important cause of morbidity and mortality. In recent years there have been important advances in understanding the molecular pathogenesis and biology of these tumors, but this has not translated into significantly improved outcomes for patients. In this consensus review from the Society for Neuro-Oncology (SNO) and the European Association of Neuro-Oncology (EANO), the current management of isocitrate dehydrogenase wildtype (IDHwt) glioblastomas will be discussed. In addition, novel therapies such as targeted molecular therapies, agents targeting DNA damage response and metabolism, immunotherapies, and viral therapies will be reviewed, as well as the current challenges and future directions for research.

Published
2020

41. Correction to: Next‑generation PET/CT imaging in meningioma—first clinical experiences using the novel SSTR‑targeting peptide [18F]SiTATE

Author

Unterrainer, Marcus, Kunte, Sophie C., Unterrainer, Lena M., Holzgreve, Adrien, Delker, Astrid, Lindner, Simon, Beyer, Leonie, Brendel, Matthias, Kunz, Wolfgang G., Winkelmann, Michael, Cyran, Clemens C., Ricke, Jens, Jurkschat, Klaus, Wängler, Carmen, Wängler, Björn, Schirrmacher, Ralf, Belka, Claus, Niyazi, Maximilian, Tonn, Joerg‑Christian, Bartenstein, Peter, and Albert, Nathalie L.

Published
2023
Full Text
View/download PDF

42. Mid-term treatment-related cognitive sequelae in glioma patients

Author

Schlömer, Sabine, Felsberg, Jörg, Pertz, Milena, Hentschel, Bettina, Löffler, Markus, Schackert, Gabriele, Krex, Dietmar, Juratli, Tareq, Tonn, Joerg Christian, Schnell, Oliver, Vatter, Hartmut, Simon, Matthias, Westphal, Manfred, Martens, Tobias, Sabel, Michael, Bendszus, Martin, Dörner, Nils, Fliessbach, Klaus, Hoppe, Christian, Reifenberger, Guido, Weller, Michael, Schlegel, Uwe, and Network, for the German Glioma

Published
2022
Full Text
View/download PDF

47. Patterns of intersectional tumor volumes in T2-weighted MRI and [18F]FET PET in adult glioma: a prospective, observational study.

Author

Weller, Jonathan, Unterrainer, Marcus, Sonderer, Markéta, Katzendobler, Sophie, Holzgreve, Adrien, Biczok, Annamaria, Harter, Patrick N., Tonn, Joerg-Christian, Albert, Nathalie L., and Suchorska, Bogdana

Subjects
CENTRAL nervous system tumors, POSITRON emission tomography, MAGNETIC resonance imaging, BRAIN tumors, ISOCITRATE dehydrogenase
Abstract

Brain tumor volumes as assessed by magnetic resonance imaging (MRI) do not always spatially overlap with biological tumor volumes (BTV) measured by [18F]Fluoroethyltyrosine positron emission tomography ([18F]FET PET). We prospectively investigated volumetric patterns based on the extent of tumor volume overlap between the two modalities. Eighty-six patients with newly diagnosed glioma who had undergone MRI and [18F]FET PET between 2007 and 2009 were included in this prospective study and (re-)classified according to CNS WHO 2021 (Classification of Tumors of the Central Nervous System by the World Health Organization). Four different patterns of volume overlap were defined mathematically according to the extent of overlap between MRI-based T2 tumor volume (non-enhancing tumor volume, nCEV) and BTVs. Progression-free (PFS) and overall survival (OS) were determined. Seventy patients were diagnosed with isocitrate dehydrogenase wildtype (IDHwt) glioblastoma and 16 with IDH-mutant glioma, respectively. The most common pattern was characterized by a larger non-contrast-enhancing tumor volume (nCEV) that enclosed all or most of the BTV and was observed in 46 patients (54%) (pattern 1). This pattern was more frequent in IDH-mutant gliomas than in IDH-wildtype glioblastoma (81% versus 47%, p = 0.02). In multivariate analyses, pattern 1 was associated with prolonged PFS (HR 0.59; 95 CI 0.34-1.0; p = 0.05), but not OS (HR 0.66; 95 CI 0.4–1.08; p = 0.1). For OS, presence of an IDH mutation (p = 0.05) and lower age (p = 0.03) were associated with prolonged OS. The spatial relation between nCEV and BTV varies within and between glioma entities. Most frequently, a larger nCEV encases the BTV. Some patients show spatially dissociated nCEVs and BTVs. Not accounting for this phenomenon in surgery or radiotherapy planning might lead to undertreatment. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results